Drug intelligence / Profile preview

small humanin-like peptide 2

Development stage
Preclinical
Modality
Peptides
Administration
Intraperitoneal, Intracerebroventricular, Systemic
01

Overview

Small humanin-like peptide 2 is a **mitochondrial-derived 26-amino-acid peptide biologic** encoded within the mitochondrial **MT-RNR2** locus and studied as an experimental research peptide rather than an approved therapeutic product. Preclinical studies describe SHLP2 as a **CXCR7 agonist** with cytoprotective, anti-apoptotic, and metabolic regulatory activity, including improvement of mitochondrial respiration and biogenesis, reduction of reactive oxygen species, insulin-sensitizing effects, suppression of food intake, promotion of thermogenesis, and protection in models of diet-induced obesity and metabolic dysfunction. It has been explored in research settings for potential relevance to **obesity, type 2 diabetes, age-related macular degeneration, Parkinson's disease, and other mitochondrial dysfunction-related disorders**, but there is no clear evidence of branded clinical development by a specific biopharmaceutical company.

Other names
small humanin-like peptide 2SHLP2SHLP-2SHLP 2
02

Targets

IAPP (Islet Amyloid Polypeptide)CXCR7 (CXC chemokine receptor 7)

Beyond the preview

Go deeper on small humanin-like peptide 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on small humanin-like peptide 2.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call